MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

-0.69% Post

-1.14% Post

-1.27% Post

-2.79% Post

-3.59% Post

Aflac Incorporated AFL	0.00	0.00%
Arcutis Biotherapeutics ARQT	0.00	0.00%
ING Groep NV Sponsored ADR ING	0.00	0.00%
MaxLinear, Inc. Class A MXL	0.00	0.00%
Nyxoah SA Ordinary Shares NYXH	0.00	0.00%

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.

Shares of MaxLinear, Inc. (NYSE:MXL) shares fell sharply during Thursday’s pre-market trading after reporting fourth-quarter results.

MaxLinear posted adjusted earnings of 1 cent per share, compared to market estimates of 1 cent per share. The company’s quarterly sales came in at $125.35 million versus expectations of $125.11 million, according to data from Benzinga Pro.

MaxLinear shares dipped 13.4% to $18.00 in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

ING Groep N.V. (NYSE:ING) shares declined 8.7% to $12.97 in pre-market trading following fourth-quarter results.
Nyxoah S.A. (NASDAQ:NYXH) shares tumbled 8.4% to $9.91 in pre-market trading after jumping around 33% on Wednesday.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares fell 8% to $5.40 in pre-market trading. Steven Cohen reported a 5.2% passive stake in Arcutis Biotherapeutics in 13G Filing.
Rocket Lab USA, Inc. (NASDAQ:RKLB) shares declined 6.8% to $4.52 in pre-market trading after the company announced a proposed offering of $275 million convertible senior notes.
Wolfspeed, Inc. (NYSE:WOLF) shares fell 6.5% to $30.45 in pre-market trading following the company's second-quarter earnings.
ZoomInfo Technologies Inc. (NASDAQ:ZI) fell 3.1% to $15.55 in pre-market trading. B of A Securities recently upgraded the stock from Neutral to Buy and raised its price target from $20 to $25.
Aflac Incorporated (NYSE:AFL) shares declined 2.1% to $82.55 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
Sanofi (NASDAQ:SNY) fell 2% to $48.88 in pre-market trading after the company posted fourth-quarter results and named François-Xavier Roger as Chief Financial Officer.

Now Read This: Apple, Honeywell International And 3 Stocks To Watch Heading Into Thursday

Don’t forget to check out our premarket coverage here

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.